ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia

Journal of Immunological Methods

Volumn 239, Issue 1-2, 2000, Pages 75-83

  Wang, B ^a   Hak, L J ^a   Relling, M V ^a,c   Pui, C H ^b,c   Woo, M H ^c   Storm, M C ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukemia; Anti asparaginase antibodies; ELISA; L Asparaginase

Indexed keywords

ASPARAGINASE; ASPARAGINASE ANTIBODY; ENZYME ANTIBODY; UNCLASSIFIED DRUG;

ACCURACY; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; PRIORITY JOURNAL; TECHNIQUE;

ABSORPTION; ASPARAGINASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERWINIA; ESCHERICHIA COLI; HORSERADISH PEROXIDASE; HUMANS; IMMUNOGLOBULIN G; INDICATORS AND REAGENTS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LINEAR MODELS; REPRODUCIBILITY OF RESULTS;

ARMORACIA RUSTICANA; CAPRA HIRCUS; ERWINIA; ERWINIA CHRYSANTHEMI; ESCHERICHIA COLI;

EID: 0034717207     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(00)00182-4     Document Type: Article

References (20)

1. Artenstein A.W., VanCott T.C., Sitz K.V., Robb M.L., Wagner K.F., Veit S.C.D., Rogers A.F., Garner R., Byron J.W., Burnett P.R., Birx D.L. Mucosal immune responses in four distinct compartments of women infected with human immunodeficiency virus type I: A comparison by site and correlation with clinical information. J. Infect. Dis. 175:1997;265.
2. Asselin B.L., Ryan D., Frantz C.N., Bernal S.D., Leavitt P., Sallan S.E., Cohen H.J. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res. 49:1989;4363.
3. Asselin B.L., Lorenson M.Y., Whitin J.C., Coppola D.J., Kende A.S. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res. 51:1991;6568.
4. Asselin B.L., Whitin J.C., Coppola D.J., Rupp I.P., Sallan S.E., Cohen H.J. Comparative pharmacokinetic studies of three asparaginase preparations. J. Clin. Oncol. 11:1993;1780.
5. Belec L., Dupre T., Prazuck T., Tevi-benissan C., Kanga J.M., Pathey O., Lu X.S., Pillot J. Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J. Infect. Dis. 172:1995;691.
6. Billett A.L., Carls A., Gelber R.D., Sallan S.E. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer. 70:1992;201.
7. Capizzi R.L., Bertino J.R., Handschumacher R.E. L-Asparaginase. Ann. Rev. Med. 21:1971;433.
8. Cheung N.-K.V., Chau I.Y., Coccia P.F. Antibody response to Escherichia coli L-asparaginase: Prognostic significance and clinical utility of antibody measurement. Am. J. Pediatr. Hematol/Oncol. 8:1986;99.
9. Dellinger C.T., Miale T.D. Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures. Cancer. 38:1976;1843.
10. Dohlwitz A., Franzen S., Holmgren A., Killander A., Killander D., Wide L., Ahstrom L. Studies on antibody formation in patients treated with L-asparaginase. Cancer Res. 33:1970;198.
11. Evans W.E., Tsiatis A., Rivera G., Murphy S.B., Dahl G.V., Denison M., Crom W.R., Barker L.F., Mauer A.M. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer. 49:1982;1378.
12. Killander D., Dohlwitz A., Engstedt L., Franzen S., Gahrton G., Gullbring B., Holm G., Holmgren A., Hoglund S., Killander A., Lockner D., Mellstedt H., Moe P.J., Palmblad J., Reizenstein P., Skarberg K.-O., Swedberg B., Uden A.-M., Wadman B., Wide L., Ahstrom L. Hypersensitivity reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer. 37:1976;220.
13. Oettgen H.F., Tallal L., Tan C.C., Murphy M.L., Clarkson B.D., Golbey R.D., Krakoff I.H., Karnofsky D.A., Burchenal J.H. Clinical experience with L-asparaginase. Cancer Res. 33:1970;219.
14. Oettgen H.F., Stephenson P.A., Schwartz M.K., Leeper R.D., Tallal L., Tan C.C., Clarkson B.D., Golbey R.B., Krakoff I.H., Karnofsky D.A., Lois Murphy M., Burchenal J.H. Toxicity of E. coli L-asparaginase in man. Cancer. 25:1970;253.
15. Park Y.K., Abuchowski A., Davis S., Davis F. Pharmacology of Escherichia coli-l-asparaginase polyethylene glycol adduct. Anticancer Res. 1:1981;373.
16. Peterson R.G., Hanschumacher R.E., Mitchell M.S. Immunological responses to L-asparaginase. J. Clin. Invest. 50:1971;1080.
17. Steuber C.P., Levy G.J., Nix W.L., Shepherd D.A., Starling K.A., Fernbach D.J. Use of L-asparaginase and cytosine arabinoside for refractory acute lymphocytic leukemia with particular reference to T-cell leukemia. Med. Pediatr. Oncol. 5:1978;33.
18. Woo M.H., Hak L.J., Storm M.C., Evans W.E., Sandlund J.T., Rivera G.K., Wang B., Pui C.-H., Relling M.V. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia. 12:1998;1527.
19. Woo M.H., Hak L.J., Storm M.C., Sandlund J.T., Ribeiro R.C., Rivera G.K., Rubnitz J.E., Harrison P.L., Wang B., Evans W.E., Pui C.-H., Relling M.V. Hypersensitivity or development of antibodies of asparaginase do not impact treatment outcome of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 18:(7):2000;1525.
20. Yoshimoto T., Nishimura H., Saito Y., Sakurai K., Kamisaki Y., Wada H., Sako M., Tsujino G., Inada Y. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia. Jpn. J. Cancer Res. (Gann). 77:1986;1264.